A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression
Science Advances · 2025
DOI: 10.1126/sciadv.adw2286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Samiksha S Raut und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Prodrugs, Tenofovir, Hepatitis B virus, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIMH NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Long-acting (LA) extended-release formulations are revolutionizing treatment and prevention of HIV infection. However, none of the existing LA therapies are active against hepatitis B virus (HBV), a common coinfection with HIV. Managing coinfection requires therapy to be effective against both viruses. Notable candidates are tenofovir (TFV) prodrugs. We have previously developed an LA TFV through a modified lipophilic ProTide strategy. Given the process chemistry challenges presented by amino acid chiral centers in ProTides, a simplified lipophilic amino acid–free crystalline phosphonate prodrug of TFV (M5TFV) has been created. Intramuscular injections of M5TFV nanosuspension (NM5TFV) were well tolerated in Sprague-Dawley rats and HBV transgenic mice. Notably, single doses at 200 and 400 milligrams per kilogram TFV equivalents produced >2.5 log 10 reduction in HBV DNA beyond 2 months in transgenic mice. Reductions of covalently closed circular DNA were seen in hepatocyte-like cells. These promising findings support further development of NM5TFV as an ultra-LA formulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Sylvia Havlik Centennial Professor of Oncology, Department of Pathology, Microbiology and Immunology, and Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA.
ORCID-Profile: Samiksha S Raut, Srijanee Das, Mojisola Ogunnaike, Samuel M Cohen, Howard E Gendelman, Larisa Y Poluektova, Benson J Edagwa, Natalia A Osna
Förderung
- NIAID NIH HHS
- NIMH NIH HHS
- NINDS NIH HHS
Zitieren
APA
Raut, S. S., Das, S., Bybee, G., Chava, H., Ogunnaike, M., Wang, W., Pathania, A. S., Hanson, B. W., Le, N. T. H., Cohen, S. M., Gendelman, H. E., Poluektova, L. Y., Edagwa, B. J., & Osna, N. A. (2025). A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression. Science Advances. https://doi.org/10.1126/sciadv.adw2286
Vancouver
Raut SS, Das S, Bybee G, Chava H, Ogunnaike M, Wang W, et al. A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression. Science Advances. 2025. doi:10.1126/sciadv.adw2286
BibTeX
@article{Raut2025,
author = {Raut, Samiksha S and Das, Srijanee and Bybee, Grace and Chava, Haritha and Ogunnaike, Mojisola and Wang, Weimin and Pathania, Anup S and Hanson, Brandon W and Le, Nam Thai Hoang and Cohen, Samuel M and Gendelman, Howard E and Poluektova, Larisa Y and Edagwa, Benson J and Osna, Natalia A},
title = {A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adw2286}
}
EUVIMED